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Abstract 
 
The attachment of the sugar D-N-acetylglucosamine (GlcNAc) with to specific serine and threonine 
residues on proteins is referred to as protein O-GlcNAcylation. O-GlcNAc transferase (OGT) is the 
enzyme responsible for carrying out the modification while O-GlcNAcase (OGA) reverses it. Protein 
O-GlcNAcylation has been implicated in a wide range of cellular processes including transcription, 
proteostasis and stress response. Dysregulation of O-GlcNAc has been linked to diabetes, cancer, 
neurodegenerative and cardiovascular disease. OGA has been proposed to be a drug target for the 
treatment of Alzheimer’s and cardiovascular disease given that increased O-GlcNAc levels appear to 
exert a protective effect. The search for specific, potent and drug-like OGA inhibitors with 
bioavailability in the brain is therefore a field of active research, requiring orthogonal high-throughput 
assay platforms. Here we describe the synthesis of a novel probe for use in a fluorescence 
polarization based assay for the discovery of inhibitors of OGA. We show that the probe is suitable for 
use with both human OGA, as well as the orthologous bacterial counterpart from Clostridium 
perfringens, CpOGA, and the lysosomal hexosaminidases HexA/B. We structurally characterize 
CpOGA in complex with a ligand identified from a fragment library screen using this assay. The 
versatile synthesis procedure could be adapted for making fluorescent probes for the assay of other 
glycoside hydrolases. 
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Introduction 
Protein O-GlcNAcylation is the dynamic and reversible modification of specific serine and threonine 
side chains on multitude of nucleocytoplasmic and mitochondrial proteins with a single β-N-
acetylglucosamine residue1. The attachment of the sugar is catalyzed by the enzyme O-GlcNAc 
transferase (OGT) and its removal by O-GlcNAcase (OGA). Both OGT and OGA are essential 
enzymes in mice, with their loss resulting in lethality2-4. Protein O-GlcNAcylation is involved in various 
cellular processes including transcription5-8, protein stability/degradation9, and stress response10-12; in 
most these processes, however, the exact role of O-GlcNAcylation is yet to be deciphered. 
Dysregulation of O-GlcNAc cycling, associated with malfunctions in the production and activity of the 
processing enzymes, is a feature of pathological conditions such as diabetes, cancer, Alzheimer’s 
disease and cardiovascular disease1, 9, 13-15. 
   The structural characterization of bacterial OGAs and more recently human OGA gave insights into 
the binding mode of O-GlcNAc proteins16-20. Schimpl et al. showed that glycosylated substrate 
peptides bind in a conserved groove in a similar conformation and orientation, adopting a “V”-shaped 
conformation with the residue side chains pointing away from the active site, explaining how a single 
enzyme can recognize > 1000 different substrates16. Inspection of the structures revealed that the 
peptide backbone forms interactions with OGA, in the -4 through the +3 position surrounding the O-
GlcNAc site16. Additional hydrophobic interactions are formed by residues in the -1 and -2 position 
and a surface exposed Tyr189 in CpOGA, which is conserved in the human OGA (Tyr69)16, 17. Studies 
revealed that mutation of Tyr69 in human OGA leads to a significant reduction in catalytic activity on 
the substrate analogue 4-methylumbelliferyl-β-D-N-acetylglucosaminide (4MU-GlcNAc) 17.  
   Structural studies of human OGT21-23 and bacterial orthologues of OGA24, 25 have allowed the 
development of inhibitors26-33 to study the function of these enzymes at the molecular and cellular 
level. In the case of OGA, potent, cell penetrant inhibitors exist29-33, and have been used for the 
identification of OGA as a potential drug target for the treatment of Alzheimer’s disease (AD) and 
cardiovascular disease34-36. Hyperphosphorylation of the protein tau resulting in the formation of 
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neurofibrillary tangles (NFTs) in AD leading to neuronal loss can be slowed by increasing O-
GlcNAcylation, which stabilizes tau, preventing its aggregation34. This study was performed using 
mice fed with the OGA inhibitor Thiamet G30. A chemically related molecule NButGT29 was shown to 
prevent the accumulation of the protein amyloid β, neuroinflammation and memory loss in another 
mouse model of AD35. With respect to cardiovascular disease, inhibition of OGA using NAG 
thiazolines and NButGT was shown to be protective and attenuate tissue necrosis after 
ischaemia/reperfusion injury36, 37. Furthermore, genetic studies have suggested that deletion of oga is 
perinatally lethal although it is not yet clear whether this essentiality is limited to early development 3, 
4. While potent and selective, the existing inhibitors of OGA possess a carbohydrate scaffold, which 
has poor drug-like properties with respect to Lipinski’s rules. Achieving therapeutic concentrations of 
these molecules in vivo requires the administration of large quantities of the drugs. Molecules with 
improved stability, pharmacology and penetrability of the blood-brain barrier are desired and the 
search for these is the subject of ongoing research, exemplified by recent studies describing the use 
of click chemistry for the rapid generation of potential OGA inhibitor libraries38 and the use of existing 
chemical libraries for the discovery of new drug-like inhibitor scaffolds39. 
   Fluorescence polarization (FP) is one of many techniques used for the analysis of ligand-protein 
interactions. The FP technique offers advantages over methods such as surface plasmon resonance 
(SPR) and biolayer interferometry (BLI) for the measurement of binding affinities of proteins to 
ligands40. It is robust, the quantities of protein/ligands required for an FP assay are comparatively low 
and neither proteins nor ligands require to be immobilized to a surface. This makes the FP assay 
completely solution-based and minimizes skewing of binding equilibrium, which could occur by 
immobilizing a protein, as this may impose constraints on structural changes that could occur upon 
ligand binding40, 41.  Also, as a solution based technique, an FP assay is more amenable to high 
throughput formats. While the OGA activity assay based on the hydrolysis of the fluorescent substrate 
4MU-GlcNAc provides a method for the discovery of OGA inhibitors24, 42, the measurement of 
inhibition constants for potent inhibitors requires long incubations periods (e.g. ~7 h for CpOGA and 
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GlcNAcstatin C)32. An advantage of an FP based OGA assay is direct measurement of binding rather 
than loss of activity, reducing assay length. The main limiting factor in the development of an FP 
assay is the requirement for a tailor-made fluorescent ligand with high affinity to the protein/receptor 
under study, which is what we report here. 
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Results and Discussion 
   Previously, we established a robust synthetic approach to a family of highly potent and selective 
OGA inhibitors, built on 8-alkylamido 2-phenethyl substituted bicyclic sugar-imidazole scaffold 
(GlcNAcstatins) 43. Here we disclose the synthesis of a fluorescently tagged derivative of the potent 
OGA inhibitor GlcNAcstatin B 1 created by the replacement of the 2-phenethyl group of the parent 
molecule with aminopropyl spacer labeled with FITC (hereafter referred to as GlcNAcstatin BF 2 (Fig. 
1)). 
 
     
Figure 1. Structures of GlcNAcstatin B (1) and GlcNAcstatin BF (2) 
 
We also report a novel FP displacement assay using GlcNAcstatin BF as a fluorescent tracer to 
measure the binding affinities of existing inhibitors to the bacterial OGA from Clostridium perfringens, 
CpOGA, as well as human OGA (hOGA).  
   We initially devised a concise synthetic scheme to access GlcNAcstatin BF 2 (Scheme 1). We 
scheduled the chemoselective installation of a fluorescent tag onto the derivative 3 bearing the 
requisite aminopropyl handle that supports the final steps in synthesis of the target compound. To 
reach 3 we devised a novel synthetic approach for the construction of the 8-alkylamido 2-substituted 
sugar-imidazole 4 by reversing the order in which the corresponding substituents would be introduced 
into the target molecule as compared to the published approach43. 
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Scheme 1. Retrosynthetic analysis of GlcNAcstatin BF 
 
Accordingly, we planned to transform the known key 2-iodo-mannose-imidazole 6 into GlcNAc-
imidazole derivative 5, which in turn was to be coupled with N-Boc propargyl amine in a Sonogashira 
reaction giving the intermediate 4. Although this previously unexplored reverse sequence lacks the 
flexibility of the previously published approach43, it sufficed for the case where synthesis of the sole 
N-acetyl derivative was required.  
    Previously, the intermediate 6 was prepared by regioselective mono-deiodination of the diiodo-
derivative 6a, which in turn was the product of a challenging bis-iodination (8 eq of NIS, 85 °C, 36 h) 
of the bicyclic sugar-imidazole 6b. The latter process was found to be unsuitable for upscaling, 
resulting in formation of varying amounts of the triply iodinated (ortho position in the p-methoxybenzyl 
(PMB) group) product, depending on the quality of NIS used. As an alternative route to intermediate 
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6, we decided to reinvestigate the cyclization of the linear 4,5-diiodoimidazole 7, which was previously 
found to be inert in a triflic anhydride mediated process 43 (Scheme 2). 
Scheme 2
a 
 
 
a Reagents and conditions: (a) Tf2O, C2H4Cl2, 65 °C; (b) PPh3, DIAD, THF, 65 °C, 1h, 85%; (c) EtMgBr, THF, 0 °C,  1 h, 
89%; (d) TFA-H2O 1:9, DCM, 1h, RT, 85%; (e) DPPA, DBU, Tol, 90 °C, 1h, 95%; (f) PPh3, THF-H2O, 65 °C, 3 h, then 
Ac2O, DIPEA, 16 RT, 85%; (g) HCCCH2NHBoc; Pd(PPh3)4, CuI, Et3N, DMF, 85 °C, 16 h, 53%; (h) H2, Pd/C, MeOH, 2 h, 
RT; (i)  HCl:TFE 1:50 , 50 °C, 2 h followed by FITC, DIPEA, DMF, RT, 1 h, 65% over two steps.  
     
We assumed that the decreased pKa of the imidazole moiety in 7 would facilitate intramolecular 
reactivity under Mitsunobu N-alkylation conditions, giving the bicyclic sugar imidazole 6a directly. The 
intermolecular Mitsunobu N-alkylation reaction of imidazoles bearing electron-withdrawing 
substituents with different alcohols, including secondary, has several precedents in the literature44, 45. 
Furthermore, Mitsunobu type cyclization of structurally similar sugar-derived 1,4-diols was 
consistently used for the synthesis of C-nucleosides including C2-imidazole and benzimidazole 
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derivatives46, 47. In our hands, reaction of the linear precursor 7 under standard Mitsunobu conditions 
(PPh3, DIAD, 65 °C) resulted in formation of the expected known bicyclic product 6a in excellent yield 
(Scheme 2). The reaction was shown to be equally applicable to multi-gram scale preparations. 
Taken together, the novel intramolecular Mitsunobu N-alkylation of 7 in conjunction with the proven 
highly efficient regioselective mono-deiodination of 6a represents a streamlined (and more economic) 
access to the key 2-iodoimidazole 6 that supersedes the triflic anhydride mediated cyclization/bis-
iodination sequence of the former approach43. 
   We have previously documented the hydrolytic stability of the BDA group in the GlcNAc-imidazoles 
43. Now we reveal that this phenomenon also works for neutral glycoimidazoles to introduce useful 
orthogonality towards acidolysis between PMB and BDA groups. Indeed, using the standard 
conditions for the deprotection of the PMB group (aqueous 90% TFA in DCM48) we were able to 
selectively remove the 8-O PMB group in 6 without affecting the DBA49 and (less surprisingly) the 
TIPS groups to obtain the monohydroxylic compound 8 in 85 % yield (Scheme 2). This 
counterintuitive deprotection protocol offers a simplified alternative to the DDQ-mediated PMB 
removal of the original approach43.   
    Using 8 as the substrate, the stereoselective azide introduction with inversion of configuration 
proceeded smoothly according to the established protocol to give gluco-imidazole 9 in a nearly 
quantitative yield. Next, a one-pot stepwise Staudinger reduction/acetylation sequence applied to 9 
gave the crucial 2-iodo-GlcNAc-imidazole 5 in high yield. The Sonogashira coupling of derivative 5 
with N-Boc propargyl amine resulted in a fair yield (53%) of the desired advanced intermediate 4. 
Overall, we have successfully implemented a novel synthetic approach for the construction of 8-
alkylamido-2 substituted sugar–imidazoles. This approach produces comparable efficiency to the 
original one on all the separate steps but Sonogashira coupling, where somewhat diminished yield 
was recorded. 
   The concluding transformation of 4 into the targeted fluorescent tracer 2 was initiated with 
hydrogenation of the triple bond to give the C-2 aminopropyl equipped derivative 10. The pivotal one-
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pot global removal of the protecting groups in 10 was efficiently achieved with 12 M HCl in 
trifluoroethanol (1:50) at 55 °C for 2 h to give the fully deprotected compound 350, 51 which was 
(without purification) treated with a slight excess of FITC in DMF to furnish the fluorescently tagged 
product 2 (Scheme 2). The reaction mixture was directly purified by reverse phase flash 
chromatography on a C18 column and the product was re-purified to homogeneity by HPLC to afford 
the desired GlcNAcstatin BF in 65% yield over the three-step sequence. 
   We next wanted to assess the use of GlcNAcstatin BF with CpOGA and hOGA in an FP assay. 
GlcNAcstatin BF bound to CpOGA with a Kd of 0.5 ± 0.2 nM (Fig. 2a) and to hOGA with a Kd of 143 ± 
29 nM (Fig. 2b). We then used GlcNAcstatin BF in displacement assays to measure the Kd of the 
inhibitors GlcNAcstatin B and GlcNAcstatin G. Consistent with previous reports 32, 33, GlcNAcstatin B 
was a better binder of CpOGA with a Ki of 6.6 nM versus 16.3 nM for GlcNAcstatin G (Fig. 2c). For 
hOGA, however, the Ki obtained for GlcNAcstatin B was 23.2 nM and for GlcNAcstatin G, it was 21.4 
nM (Fig. 2d). The absolute Ki values obtained for these inhibitors are not consistent with previously 
reported Ki values obtained using the 4MU-NAG based activity assay
32, 33. In addition to the variability 
expected from using different methods, this could be due to the differences in the assay buffer and 
pH used or the different N-terminal truncation of the construct used in this study. Dorfmueller et al., 
used the McIlvaine buffer system at pH 5.7/7.3 32, 33, while here we use Tris buffered saline (TBS) at 
pH 7.5. The Ki values obtained with the FP assay for the binding of CpOGA to GlcNAcstatin G and 
another potent OGA inhibitor Thiamet G30 are consistent with those obtained using surface plasmon 
resonance (SPR) performed using the same assay buffer (Supplementary Fig. S1); the binding 
affinity of hOGA for Thiamet G using the FP assay is shown in Supplementary Fig. S2. These proof-
of-concept experiments establish the fluorescence polarization displacement assay using 
GlcNAcstatin BF as a convenient method for evaluating affinity of OGA inhibitors. 
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 Figure 2. Binding affinity of GlcNAcstatin BF and two inhibitors of the GlcNAcstatin family to CpOGA and hOGA. 
FP assay showing the binding of GlcNAcstatin BF to a) CpOGA and b) hOGA. Binding was measured by incubating for 10 
min (CpOGA) and 180 min (hOGA) at a fixed concentration of labeled probe ([GBFCpOGA] = 0.5 nM, [GBFhOGA] = 50 nM) 
with varying concentrations of enzyme. Data points were fitted to a one-site specific-binding equation using Prism 
(GraphPad).  Experiments were performed in triplicate and error bars represent standard error of the mean. Dose-
response curves from the fluorescence polarization assay showing the displacement from c) CpOGA or d) hOGA of a 
fixed concentration of fluorescent probe by increasing concentrations of GlcNAcstatin B or GlcNAcstatin G. Highest 
amount of probe bound to enzymes in the absence of inhibitors was set as 100%. Data points were fitted to a four-
parameter equation for dose-dependent inhibition using Prism (GraphPad). Experiments were performed in triplicate and 
error bars represent standard error of the mean. A summary including Hill Slopes can be found in Supplementary Material 
Table 1. 
 
To expand the applicability of the suggested assay system for the high-throughput screening of 
custom compound libraries, we decided to evaluate the Maybridge Ro3 1000 fragment library towards 
CpOGA as a target. This library consists of fragments that adhere to the ‘rule of three’ (Ro3) 
(molecular weight ≤ 300 Da, no more than 3 hydrogen bond donors/acceptors, cLogP ≤ 3). The 
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screen was performed under experimental conditions matching those used in the displacement of 
GBF by Thiamet G and GlcNAcstatin G (Supplementary material Fig. S3). 
 
The quality of both screens was estimated by calculating Z′ value across the controls on a given 
plate 1, which is a measure of the statistical effect size and therefore the suitability of a high-
throughput assay system. In our hands, we consistently saw Z′ values for each plate between 0.73 
– 0.84 with respect to the standard readings, with a Z′ value of 0.66 for readings across all four 
plates. We chose to identify compounds as hits if they reduced the maximum polarization by ≥ 40%, 
resulting in a list of 15 initial hits. Subsequently, the initial hits were advanced into the second round 
of testing, in which we determined the Ki values by measuring the displacement of GlcNAcstatin BF in 
a dose-dependent manner. Out of the 15 initial hits (F1-F15, Supplementary Material Fig. 3, 
Supplementary Material Table 2), 8 were confirmed as binders of CpOGA with apparent Ki values 
between 9 – 150 µM.  
 
Binding of a fragment hit to Tyr189 and Asp401 blocks GlcNAcstatin BF and substrate binding 
To further validate the fragments identified as binders in the HTS screen, we performed 
macromolecular x-ray crystallography to identify the binding mode of a subset of these hits. We 
managed to solve the structure of CpOGA in complex with 5-(trifluoromethyl)-2,3-dihydro-1H-1,4-
diazepine (Fragment F8 hereafter referred to as 5TFD, apparent Ki = 146 µM, Fig. 3A). We collected 
synchrotron diffraction data to 2.6 Å (Supplementary material Table 3) allowing structure solution by 
molecular replacement and subsequent refinement (final Rwork/Rfree = 0.17/0.22). There was 
continuous |Fo|-|Fc| electron density for the fragment (Fig. 3B). 5TFD binds proximal to the active site 
pocket, forming hydrophobic stacking interactions with Tyr189 (Fig 3B). Additionally, the secondary 
amine of 5TFD forms a hydrogen bond with the backbone carbonyl oxygen of Asp401 (Fig. 3B). Tyr189 
has been previously identified to be important for substrate binding, forming hydrophobic interactions 
with the substrate peptide backbones16. When compared to a structure of CpOGA in complex with 
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GlcNAcstatin F (Fig. 3 C, PDBID: 2XPK 52), a nM inhibitor of CpOGA designed to mimic the reaction 
intermediate, 5TFD forms different interactions. However, taking into account the longer linker and 
presence of the fluorescein group present in GlcNAcstatin BF it is possible for 5TFD to form a steric 
barrier for proper GBF binding. Thus, the 5TFD fragment bound to Tyr189 and Asp401, is able to block 
binding of GlcNAcstatin BF and glycopeptide substrates. 
 
Figure 3. Binding affinity of 5FTD and binding mode of 5FTD and GlcNAcstatin C to CpOGA. a) Dose-response 
curves from the fluorescence polarization assay showing the displacement from CpOGA of a fixed concentration of 
fluorescent probe by increasing concentrations of 5FTD. Highest amount of probe bound to enzymes in the absence of 
inhibitors was set as 100% and a fictive concentration of 10 M set as 0%. Data points were fitted to a four-parameter 
equation for dose-dependent inhibition using Prism (GraphPad). Experiments were performed in triplicate and error bars 
represent standard error of the mean. A summary including Hill Slopes can be found in Supplementary Material Table 2. 
Structure of CpOGA in complex with b) 5FTD and c) GlcNAcstatin F (PDBID 2XPK 52). The protein is shown as grey 
cartoon with active site residues shown as sticks. Ligands are shown as green sticks. Hydrogen bonds between ligands 
and active site residues are shown as dashed black lines. The unbiased |Fo|-|Fc| electron density map for 5FTD is shown 
as blue mesh contoured at 2 σ. 
 
GlcNAcstatin BF may not only be useful to measure the binding of ligands to OGA, but also to 
enzymes of related glycoside hydrolase families such as GH20, to which human HexA/B belong. This 
is because GlcNAcstatin B itself, while potent, is not a selective inhibitor of OGA32 and also targets 
HexA/HexB. We were able to determine an apparent Kd of ~ 4 µM (Supplementary Material Figure 4) 
for GlcNAcstatin BF to HexA/B isolated from bovine kidneys. HexA/HexB have recently been 
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explored as targets for enzyme enhancement therapy to treat the lysosomal storage diseases Tay-
Sachs and Sandhoff disease53 and an FP based assay offers an alternative to activity assays for the 
screening of fragments/compounds that bind to these proteins.  
 
Here we have reported the design and synthesis of the novel fluorescent probe GlcNAcstatin BF to 
support miniaturized OGA high-throughput assays. To synthesize the target compound we 
established a novel synthetic approach for the construction of the 8-N alkylamide 2-substiuted sugar–
imidazoles by reversing the order of the introduction of the respective substituents into the key 
intermediate as compared to the original approach. As part of the study, we also developed a novel 
method for the synthesis of bicyclic sugar-imidazoles via intramolecular Mitsunobu N-alkylation of 4,5-
diiodoimidazoles to supersede the challenging sequence of the former approach. We successfully 
applied a simplified counterintuitive acid hydrolysis procedure for the removal of the PMB protection 
in the presence of cyclic BDA, the product of the unique substrate-induced orthogonality between 
PMB and DBA groups. Notably, we established a fast and high yielding procedure for the global 
deprotection of the penultimate synthetic intermediate including removal of the notoriously stable BDA 
group that constitutes an expedient alternative to the TFA based method previously used for the 
GlcNAcstatin synthesis. We have shown that GlcNAcstatin BF is suitable for use in fluorescence 
polarization assays to measure the binding affinity of OGA inhibitors and identify novel binders from a 
high-throughput screen of a 1000-member fragment library. Finally, we solved the structure of 
CpOGA in complex with a binder identified in the screen and were able to show that it binds to 
Tyr189, an important residue for substrate binding. 
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Materials and Methods 
 
Crystallography and structure solution 
CpOGA was concentrated to 40 mg mL-1 in 25 mM Tris-HCl pH 8.0, 20 mM NaCl, 0.5 mM TCEP. 
Sitting-drop vapor diffusion crystallization experiments were performed by mixing drops in a 1:1 ratio 
of CpOGA and 0.175 M CdSO4, 0.1 M sodium acetate pH 7.5 and needle shaped crystals appeared 
after 3-4 days. A 5FTD fragment complex was achieved by transferring crystals into a drop containing 
10 mM 5FTD in 0.175 M CdSO4, 0.1 M sodium acetate pH 7.5, 1% DMSO for 4 h prior to 
cryoprotection with 20% glycerol in mother liquor saturated with 5TFD. Diffraction data was collected 
at the European Synchrotron Radiation Facility (ESRF) on beamline ID30A-3, were processed with 
XDS54 and scaled to 2.6 Å using aimless55. 5% of total reflections were set aside as an Rfree test set. 
Crystals belonged to space group P61 with one molecule per asymmetric unit, a solvent content of 
72% and a Matthews coefficient of 4.5. The structures were solved with MOLREP56, using chain A of 
PDB 2YDS16 as a search model. The structure was fully refined using iterative cycles of Refmac557 
and COOT58. Ligand topology was generated using PRODRG59. X-ray diffraction data collection and 
structure refinement statistics can be found in the supplementary material (Supplementary Material 
Table 3). 
 
Fluorescence Polarization  
Experiments were performed in PerkinElmer, black, 384-well plates and millipolarization units 
measured using a Pherastar FS plate reader (BMG LABTECH) at excitation and emission 
wavelengths of 485 nm and 520 nm, respectively. For determination of the equilibrium dissociation 
constant (Kd) of CpOGA
 and hOGA for GlcNAcstatin BF, 0.5 nM/50 nM of the probe was incubated 
with a range of concentrations of protein in 25 µL/ 30µL total reaction volume containing 1 x TBS (25 
mM Tris, 150 mM NaCl, pH 7.5) buffer and a final concentration of 1-2% DMSO. Reactions were 
allowed to stand at room temperature for 10 min for CpOGA and 3 h for hOGA, after which 
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polarization was measured (equilibrium was reached within these time points). Readings were 
corrected for background emissions from reactions without enzyme and the Kd was determined by 
fitting a non-linear regression curve with Prism (GraphPad).  To avoid receptor depletion, reaction 
mixtures for competition binding experiments contained 1 nM fluorescent probe for CpOGA and 50 
nM for hOGA, 7 nM of CpOGA/250 nM hOGA (receptor) and a range of concentrations of inhibitors in 
the aforementioned reaction conditions. The largest amount of fluorescent probe bound to the 
receptors in the absence of competing ligands was set as 100%. IC50 values were determined by 
fitting dose-response curves with Prism (GraphPad) and converted to Kd as outlined elsewhere
60. All 
experiments were performed in triplicate. 
 
High-throughput screen of the Maybridge Ro3 1000 fragment library 
The Maybridge Ro3 1000 fragment library (Maybridge) screen was performed in black, 384-well 
plates (PerkinElemer). Displacement of GlcNAcstatin BF was measured by adding 25 µL of 7 nM 
CpOGA and 1 nM GlcNAcstatin BF in assay buffer (0.1 M Tris-HCl pH 7.4, 150 mM NaCl, 1% DMSO) 
to assay plates containing 50 nL of a 0.1 M fragment solutions in DMSO, resulting in a final assay 
concentration of 200 µM. The plates were allowed to stand for 10 minutes in the dark before reading 
polarization on a Pherastar FS plate reader (BMG Labtech) at excitation and emission wavelengths of 
485 nm and 520 nm, respectively. Readings were corrected for background polarization from 
reactions containing only 1 nM GlcNAcstatin BF in assay buffer and normalised to readings 
containing 1% DMSO. Fragments displacing GlcNAcstatin BF by ≥ 40% were classified as hits and 
were advanced for Ki value determination. Competition binding experiments were conducted under 
the same assay conditions in 0.1 M Tris-HCl pH 7.4, 150 mM NaCl, 2% DMSO and varying 
concentrations of fragments. Ki values were calculated as described above. 
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Accession codes 
The atomic coordinates and structure factors have been deposited in the Protein Data Bank61 under 
the accession code 5OXD. 
 
Supporting information 
The Supporting Information, including synthetic procedures and spectral data for all new compounds, 
methods, figures and tables as well as the compound characterization checklist and the validation 
report of the deposited structure are available free of charge via the Internet. 
 
Acknowledgements 
We thank the European Synchrotron Radiation Facility (ESRF) for beam time on ID30A-3 and 
assistance. This work was funded by a Wellcome Trust Senior Research Fellowship (WT087590MA) 
to DMFvA. We would like to hank Dr. M. Schimpl for purifying hOGA.  
 
Author Contributions 
The study was conceived by VSB, NS and DMFvA. Synthesis was performed by VSB; protein 
purification, protein biotinylation and FP assays were performed by NS; KR performed HTS, FP and 
hit-validation assays and structural biology; cloning was performed by ATF and SPR was performed 
by TA and IHN. Data were analysed by all authors. The manuscript was written by VSB, NS, KR and 
DMFvA.   
Page 17 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
References 
 
[1] Hart, G. W., Slawson, C., Ramirez-Correa, G., and Lagerlof, O. (2011) Cross talk between O-
GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease, Annu. 
Rev. Biochem. 80, 825-858. 
[2] Shafi, R., Iyer, S. P., Ellies, L. G., O'Donnell, N., Marek, K. W., Chui, D., Hart, G. W., and Marth, J. D. (2000) 
The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem 
cell viability and mouse ontogeny, Proc. Natl. Acad. Sci. U. S. A. 97, 5735-5739. 
[3] Yang, Y. R., Song, M., Lee, H., Jeon, Y., Choi, E. J., Jang, H. J., Moon, H. Y., Byun, H. Y., Kim, E. K., Kim, D. H., 
Lee, M. N., Koh, A., Ghim, J., Choi, J. H., Lee-Kwon, W., Kim, K. T., Ryu, S. H., and Suh, P. G. (2012) O-
GlcNAcase is essential for embryonic development and maintenance of genomic stability, Aging 
Cell 11, 439-448. 
[4] Hanover, J., Keembiyehetty, C., Wang, P., Comly, M., Dwyer, N., Krause, M., and Love, D. (2010) Mouse 
O-Glcnacase Knockout Reveals Roles for O-Glcnac Cycling in Development, Metabolism and 
Epigenetics, Glycobiology 20, 1453-1453. 
[5] Ranuncolo, S. M., Ghosh, S., Hanover, J. A., Hart, G. W., and Lewis, B. A. (2012) Evidence of the 
involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in 
vivo, J. Biol. Chem. 
[6] Fujiki, R., Hashiba, W., Sekine, H., Yokoyama, A., Chikanishi, T., Ito, S., Imai, Y., Kim, J., He, H. H., Igarashi, 
K., Kanno, J., Ohtake, F., Kitagawa, H., Roeder, R. G., Brown, M., and Kato, S. (2011) GlcNAcylation of 
histone H2B facilitates its monoubiquitination, Nature 480, 557-U188. 
[7] Chen, Q., Chen, Y., Bian, C., Fujiki, R., and Yu, X. (2013) TET2 promotes histone O-GlcNAcylation during 
gene transcription, Nature 493, 561-564. 
[8] Deplus, R., Delatte, B., Schwinn, M. K., Defrance, M., Mendez, J., Murphy, N., Dawson, M. A., Volkmar, M., 
Putmans, P., Calonne, E., Shih, A. H., Levine, R. L., Bernard, O., Mercher, T., Solary, E., Urh, M., 
Daniels, D. L., and Fuks, F. (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation 
through OGT and SET1/COMPASS, EMBO J. 32, 645-655. 
[9] Yang, W. H., Park, S. Y., Nam, H. W., Kim do, H., Kang, J. G., Kang, E. S., Kim, Y. S., Lee, H. C., Kim, K. S., and 
Cho, J. W. (2008) NFkappaB activation is associated with its O-GlcNAcylation state under 
hyperglycemic conditions, Proc. Natl. Acad. Sci. U. S. A. 105, 17345-17350. 
[10] Zachara, N. E., and Hart, G. W. (2004) O-GlcNAc a sensor of cellular state: the role of 
nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and 
stress, Biochim. Biophys. Acta 1673, 13-28. 
[11] Zachara, N. E., O'Donnell, N., Cheung, W. D., Mercer, J. J., Marth, J. D., and Hart, G. W. (2004) Dynamic 
O-GlcNAc modification of nucleocytoplasmic proteins in response to stress - A survival response of 
mammalian cells, Journal of Biological Chemistry 279, 30133-30142. 
[12] Liu, J., Pang, Y., Chang, T., Bounelis, P., Chatham, J. C., and Marchase, R. B. (2006) Increased 
hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection 
against calcium paradox and ischemia, Journal of Molecular and Cellular Cardiology 40, 303-312. 
[13] Erickson, J. R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., Copeland, R. J., Despa, F., Hart, G. W., 
Ripplinger, C. M., and Bers, D. M. (2013) Diabetic hyperglycaemia activates CaMKII and 
arrhythmias by O-linked glycosylation, Nature 502, 372-376. 
[14] Marsh, S. A., Powell, P. C., Dell'Italia, L. J., and Chatham, J. C. (2013) Cardiac O-GlcNAcylation blunts 
autophagic signaling in the diabetic heart, Life Sciences 92, 648-656. 
[15] Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Vocadlo, D. 
J., Liu, F., and Gong, C. X. (2012) Differential effects of an O-GlcNAcase inhibitor on tau 
phosphorylation, PLoS ONE 7, e35277. 
[16] Schimpl, M., Borodkin, V. S., Gray, L. J., and van Aalten, D. M. (2012) Synergy of peptide and sugar in 
O-GlcNAcase substrate recognition, Chem Biol 19, 173-178. 
Page 18 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[17] Schimpl, M., Schuttelkopf, A. W., Borodkin, V. S., and van Aalten, D. M. (2010) Human OGA binds 
substrates in a conserved peptide recognition groove, Biochem J 432, 1-7. 
[18] Li, B., Li, H., Lu, L., and Jiang, J. (2017) Structures of human O-GlcNAcase and its complexes reveal a 
new substrate recognition mode, Nat Struct Mol Biol 24, 362-369. 
[19] Roth, C., Chan, S., Offen, W. A., Hemsworth, G. R., Willems, L. I., King, D. T., Varghese, V., Britton, R., 
Vocadlo, D. J., and Davies, G. J. Structural and functional insight into human O-GlcNAcase. 
[20] Elsen, N. L., Patel, S. B., Ford, R. E., Hall, D. L., Hess, F., Kandula, H., Kornienko, M., Reid, J., Selnick, H., 
Shipman, J. M., Sharma, S., Lumb, K. J., Soisson, S. M., and Klein, D. J. (2017) Insights into activity 
and inhibition from the crystal structure of human O-GlcNAcase, Nat Chem Biol. 
[21] Lazarus, M. B., Nam, Y., Jiang, J., Sliz, P., and Walker, S. (2011) Structure of human O-GlcNAc 
transferase and its complex with a peptide substrate, Nature 469, 564-567. 
[22] Lazarus, M. B., Jiang, J., Gloster, T. M., Zandberg, W. F., Whitworth, G. E., Vocadlo, D. J., and Walker, S. 
(2012) Structural snapshots of the reaction coordinate for O-GlcNAc transferase, Nat. Chem. Biol. 
8, 966-968. 
[23] Schimpl, M., Zheng, X., Borodkin, V. S., Blair, D. E., Ferenbach, A. T., Schuttelkopf, A. W., Navratilova, I., 
Aristotelous, T., Albarbarawi, O., Robinson, D. A., Macnaughtan, M. A., and van Aalten, D. M. (2012) 
O-GlcNAc transferase invokes nucleotide sugar pyrophosphate participation in catalysis, Nat. 
Chem. Biol. 8, 969-974. 
[24] Rao, F. V., Dorfmueller, H. C., Villa, F., Allwood, M., Eggleston, I. M., and van Aalten, D. M. (2006) 
Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis, EMBO J. 
25, 1569-1578. 
[25] Dennis, R. J., Taylor, E. J., Macauley, M. S., Stubbs, K. A., Turkenburg, J. P., Hart, S. J., Black, G. N., 
Vocadlo, D. J., and Davies, G. J. (2006) Structure and mechanism of a bacterial beta-
glucosaminidase having O-GlcNAcase activity, Nature Structural & Molecular Biology 13, 365-371. 
[26] Gross, B. J., Kraybill, B. C., and Walker, S. (2005) Discovery of O-GlcNAc transferase inhibitors, J Am 
Chem Soc 127, 14588-14589. 
[27] Gloster, T. M., Zandberg, W. F., Heinonen, J. E., Shen, D. L., Deng, L., and Vocadlo, D. J. (2011) Hijacking 
a biosynthetic pathway yields a glycosyltransferase inhibitor within cells, Nat. Chem. Biol. 7, 174-
181. 
[28] Borodkin, V. S., Schimpl, M., Gundogdu, M., Rafie, K., Dorfmueller, H. C., Robinson, D. A., and van 
Aalten, D. M. (2014) Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase 
inhibitors, Biochem J 457, 497-502. 
[29] Macauley, M. S., Whitworth, G. E., Debowski, A. W., Chin, D., and Vocadlo, D. J. (2005) O-GlcNAcase 
uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-
inspired inhibitors, J. Biol. Chem. 280, 25313-25322. 
[30] Macauley, M. S., Shan, X., Yuzwa, S. A., Gloster, T. M., and Vocadlo, D. J. (2010) Elevation of Global O-
GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or 
Perturb Glucohomeostasis (vol 17, pg 949, 2010), Chem. Biol. 17, 1161-1161. 
[31] Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., Shepherd, S. M., Shpiro, N. A., and van Aalten, D. M. F. 
(2006) GlcNAcstatin: A picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-
GlcNAcylation levels, J Am Chem Soc 128, 16484-16485. 
[32] Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., and van Aalten, D. M. (2009) GlcNAcstatins are 
nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation, Biochem. J. 
420, 221-227. 
[33] Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., Zheng, X., Kime, R., Read, K. D., and van Aalten, D. M. 
(2010) Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal 
hexosaminidases, Chem. Biol. 17, 1250-1255. 
[34] Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., and Vocadlo, D. J. 
(2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation, Nat. 
Chem. Biol. 8, 393-399. 
Page 19 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[35] Kim, C., Nam, D. W., Park, S. Y., Song, H., Hong, H. S., Boo, J. H., Jung, E. S., Kim, Y., Baek, J. Y., Kim, K. S., 
Cho, J. W., and Mook-Jung, I. (2013) O-linked beta-N-acetylglucosaminidase inhibitor attenuates 
beta-amyloid plaque and rescues memory impairment, Neurobiol. Aging 34, 275-285. 
[36] Laczy, B., Marsh, S. A., Brocks, C. A., Wittmann, I., and Chatham, J. C. (2010) Inhibition of O-GlcNAcase 
in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-
GlcNAc-dependent manner, Am. J. Physiol. Heart Circ. Physiol. 299, H1715-1727. 
[37] Champattanachai, V., Marchase, R. B., and Chatham, J. C. (2008) Glucosamine protects neonatal 
cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased 
mitochondrial Bcl-2, Am. J. Physiol. Cell Physiol. 294, C1509-1520. 
[38] Li, T., Guo, L., Zhang, Y., Wang, J., Li, Z., Lin, L., Zhang, Z., Li, L., Lin, J., Zhao, W., Li, J., and Wang, P. G. 
(2011) Design and synthesis of O-GlcNAcase inhibitors via 'click chemistry' and biological 
evaluations, Carbohydr. Res. 346, 1083-1092. 
[39] Dorfmueller, H. C., and van Aalten, D. M. F. (2010) Screening-based discovery of drug-like O-
GlcNAcase inhibitor scaffolds, Febs Letters 584, 694-700. 
[40] Rossi, A. M., and Taylor, C. W. (2011) Analysis of protein-ligand interactions by fluorescence 
polarization, Nat. Protocols 6, 365-387. 
[41] Peterson, K. J., Sadowsky, J. D., Scheef, E. A., Pal, S., Kourentzi, K. D., Willson, R. C., Bresnick, E. H., 
Sheibani, N., and Gellman, S. H. (2008) A fluorescence polarization assay for identifying ligands 
that bind to vascular endothelial growth factor, Analytical Biochemistry 378, 8-14. 
[42] (1981) Isolation and further characterization of bovine brain hexosaminidase C, Biochimica et 
Biophysica Acta (BBA) - Enzymology 659, 255 - 266. 
[43] Borodkin, V. S., and van Aalten, D. M. F. (2010) An efficient and versatile synthesis of GlcNAcstatins-
potent and selective O-GlcNAcase inhibitors built on the tetrahydroimidazo[1,2-a]pyridine 
scaffold, Tetrahedron 66, 7838-7849. 
[44] Zolle, I. M., Berger, M. L., Hammerschmidt, F., Hahner, S., Schirbel, A., and Peric-Simov, B. (2008) New 
selective inhibitors of steroid 11 beta-hydroxylation in the adrenal cortex. Synthesis and 
structure-activity relationship of potent Etomidate analogues, J Med Chem 51, 2244-2253. 
[45] Laha, J. K., and Cuny, G. D. (2011) Synthesis of Fused Imidazoles, Pyrroles, and Indoles with a Defined 
Stereocenter alpha to Nitrogen Utilizing Mitsunobu Alkylation Followed by Palladium-Catalyzed 
Cyclization, J Org Chem 76, 8477-8482. 
[46] Guianvarc'h, D., Fourrey, J. L., Dau, M., Guerineau, V., and Benhida, R. (2002) Stereocontrolled 
synthesis of heterocyclic C-nuclcosides. Protecting group effect and molecular modeling studies, J 
Org Chem 67, 3724-3732. 
[47] Yokoyama, M., Tanabe, T., Toyoshima, A., and Togo, H. (1993) SYNTHESIS OF C-NUCLEOSIDES 
HAVING TYPICAL AROMATIC HETEROCYCLES AS THE BASE MOIETY, Synthesis-Stuttgart, 517-
520. 
[48] Yan, L., and Kahne, D. (1995) P-Methoxybenzyl Ethers as Acid-Labile Protecting Groups in 
Oligosaccharide Synthesis, Synlett, 523-524. 
[49] Hense, A., Ley, S. V., Osborn, H. M. I., Owen, D. R., Poisson, J. F., Warriner, S. L., and Wesson, K. E. 
(1997) Direct preparation of diacetals from 1,2-diketones and their use as 1,2-diol protecting 
groups, J Chem Soc Perk T 1, 2023-2031. 
[50] Corey, E. J., Li, W. D., and Reichard, G. A. (1998) A new magnesium-catalyzed doubly 
diastereoselective anti-aldol reaction leads to a highly efficient process for the total synthesis of 
lactacystin in quantity, J Am Chem Soc 120, 2330-2336. 
[51] Palladino, P., and Stetsenko, D. A. (2012) New TFA-Free Cleavage and Final Deprotection in Fmoc 
Solid-Phase Peptide Synthesis: Dilute HCl in Fluoro Alcohol, Org Lett 14, 6346-6349. 
[52] Dorfmueller, H. C., Borodkin, V. S., Schimpl, M., Zheng, X., Kime, R., Read, K. D., and van Aalten, D. M. 
(2010) Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal 
hexosaminidases, Chem Biol 17, 1250-1255. 
Page 20 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[53] Tropak, M. B., Blanchard, J. E., Withers, S. G., Brown, E. D., and Mahuran, D. (2007) High-throughput 
screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as 
pharmacological chaperones, Chem. Biol. 14, 153-164. 
[54] Kabsch, W. (2010) Xds, Acta Crystallogr D Biol Crystallogr 66, 125-132. 
[55] Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, 
E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., 
Powell, H. R., Read, R. J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current 
developments, Acta Crystallogr D Biol Crystallogr 67, 235-242. 
[56] Vagin, A., and Teplyakov, A. (2010) Molecular replacement with MOLREP, Acta Crystallographica 
Section D 66, 22-25. 
[57] <Murshudov, Vagin, Dodson - 1997 - Refinement of macromolecular structures by the maximum-
likelihood method.pdf>. 
[58] Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot, Acta 
Crystallogr D Biol Crystallogr 66, 486-501. 
[59] Schuttelkopf, A. W., and van Aalten, D. M. F. (2004) PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes, Acta Crystallographica Section D 60, 1355-1363. 
[60] Nikolovska-Coleska, Z., Wang, R., Fang, X., Pan, H., Tomita, Y., Li, P., Roller, P. P., Krajewski, K., Saito, N. 
G., Stuckey, J. A., and Wang, S. (2004) Development and optimization of a binding assay for the 
XIAP BIR3 domain using fluorescence polarization, Anal. Biochem. 332, 261-273. 
[61] Berman, H. M. a. W. J. a. F. Z. a. G. G. a. B. T. N. a. W. H. a. S. I. N. a. B. P. E. (2000) The Protein Data 
Bank, Nucleic Acids Research 28, 235-242. 
 
Page 21 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
High affinity fluorescent tracer Hightroughput OGA 
Fluorescent Polarization Assay
OGA inhibitorsN
NHO
N
S
N O
O
OH
OH
HO
NHAc
HO
O
H
H
Page 22 of 22
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
